Classical Hodgkin lymphoma
Conditions
Interventions
None listed
Sponsors
HORIZON study investigators
National Cancer Center Research and Development fund (29-A-3)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) The patients who were histologically diagnosed as having classical Hodgkin lymphoma (cHL) based on WHO classification 2017 at the institution from January 2007 to December 2016. 2) The age at the diagnosis of classic Hodgkin lymphoma was 61 years old or older.
Exclusion criteria
Exclusion criteria: 1) Positive for HIV 2) Patients who received first-line treatment outside the study institution 3) Patients who were not treated or managed by the hematologists in each study institution (ex. Second opinion) 4) Patients who were diagnosed as having methotrexate-associated lymphoproliferative disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year overall survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) 5-year progression-free survival rate 2) 5-year event-free survival rate 3) Overall response rate and complete response rate of first-line therapy 4) The rate of bleomycin lung toxicity (BLT) 5) The rate of patients who completed 100%-dose ABVD therapy 6) The average relative dose-intensity of ABVD therapy 7) Charlson Comorbidity Index (CCI) score at the baseline 8) Investigation of pathological biomarkers | — |
Countries
Japan
Contacts
Public ContactShinichi Makita
National Cancer Center Hospital Department of Hematology
Outcome results
None listed